5α-reductase activity in the prostate

Urology

Volumn 58, Issue 6 SUPPL. 1, 2001, Pages 17-24

  Steers, William D ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; FR 146687; ISOENZYME; LY 320236; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; NITRIC OXIDE SYNTHASE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; VASCULOTROPIN; ENZYME INHIBITOR; TESTOSTERONE 5 ALPHA REDUCTASE;

APOPTOSIS; BASAL CELL; BLOOD VESSEL; CLINICAL TRIAL; CONFERENCE PAPER; CORPUS CAVERNOSUM; CRYPTORCHISM; ENZYME DEFICIENCY; EPIDIDYMIS; EPITHELIUM CELL; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIVER; MALE; MALE FERTILITY; MOUSE; NERVE CELL; NONHUMAN; ORGAN GROWTH; ORGANOGENESIS; PHENOTYPE; PREPUCE; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SEMINAL VESICLE; SKIN; STROMA CELL; TESTIS; TESTOSTERONE METABOLISM; UROGENITAL SYSTEM; ANIMAL; CELL CULTURE; DRUG EFFECT; EMBRYOLOGY; ENZYMOLOGY; FORECASTING; GENETICS; MALE INFERTILITY; METABOLISM; MOUSE MUTANT; MUTATION; PENIS; PENIS ERECTION; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANIMAL; CRYPTORCHIDISM; ENZYME INHIBITORS; FINASTERIDE; FORECASTING; HUMAN; INFERTILITY, MALE; ISOENZYMES; MALE; MICE; MICE, KNOCKOUT; MUTATION; PENILE ERECTION; PENIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STANOLONE; TESTIS; TESTOSTERONE 5-ALPHA-REDUCTASE; TUMOR CELLS, CULTURED;

EID: 0035652497     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01299-7     Document Type: Conference Paper

References (46)

1. Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia
2. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation; dose-response studies
3. Localization by in situ hybridization of steroid 5 alpha-reductase isozyme gene expression in the human prostate and preputial skin
4. 5α-Reductase inhibitors
5. Differential methylation in steroid 5 alpha-reductase isozyme genes in epididymis, testis, and liver of the adult rat
6. Efficacy of various natural and synthetic androgens to induce ductal branching morphogenesis in the developing anterior rat prostate
7. Familial incomplete male pseudohermaphroditism, type 2; decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias
8. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta)
9. Molecular biology of androgen action; testosterone/dihydrotestosterone receptor and androgen 5 alpha-reductase in the human foreskin
10. 5 Alpha-reductase type 2 mutations are present in some boys with isolated hypospadias
11. Androgen receptor levels and 5 alpha-reductase activities in preputial skin and chordee tissue of boys with isolated hypospadias
12. Identification of genes expressed in the rat prostate that are modulated differently by castration and finasteride treatment
13. Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate
14. Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance; a prospective clinical study
15. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels
16. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia
17. Long-term effects of finasteride on prostate tissue composition
18. Estradiol and high-dose testosterone treatment causes changes in cynomolgus monkey prostate volume and histology identical to those caused by testosterone alone
19. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor; morphological changes in patients who fail to respond
20. Finasteride in the treatment of benign prostatic hypertrophy; an update: new indications for finasteride therapy
21. Treatment of prostatic bleeding; suppression of angiogenesis by androgen deprivation
22. Effects of finasteride and bicalutamide on prostatic blood flow in rats
23. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts
24. Differences in steroid 5 alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue
25. 5 Alpha-reductase isozymes and aromatase are differentially expressed and active in the androgen-independent human prostate cancer cell lines DU145 and PC3
26. Effect of the 5 alpha-reductase inhibitor PNU 156765, alone or in combination with flutamide, in the Dunning R3327 prostatic carcinoma model in rats
27. A polymorphism of the 5 alpha-reductase gene and its association with prostate cancer; a case-control analysis
28. The V89L polymorphism in the 5 alpha-reductase type 2 gene and risk of prostate cancer
29. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study
30. 5 Alpha-reductase activity in human fetal testis
31. Regional distribution of 5 alpha-reductase type 1 and type 2 mRNA along the nonhuman primate (Macaca fascicularis) epididymis
32. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study; V, localization of higher 5 alpha-reductase activity to the reproductive tract in oligozoospermic men administered supraphysiological doses of testosterone
33. Testosterone-dependent restoration of spermatogenesis in adult rats is impaired by a 5 alpha-reductase inhibitor
34. Steady state steroid 5 alpha-reductase messenger ribonucleic acid levels and immunocytochemical localization of the type 1 protein in the rat testis during postnatal development
35. Developmental pattern of 5 alpha-reductase activity in the rat gubernaculum
36. Effects of flutamide and finasteride on rat testicular descent
37. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum
38. Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat
39. Up-regulation of the levels of androgen receptor and its mRNA by androgens in smooth muscle cells from rat penis
40. Attenuation by 5 alpha-reductase inhibitor of the activational effect of testosterone propionate on penile erections in castrated male rats
41. The 5 alpha-reductase in the central nervous system; expression and modes of control
42. Genetic analysis of male pattern baldness and the 5 alpha-reductase genes
43. Z-350, a novel compound with alpha 1-adrenoceptor antagonistic and steroid 5 alpha-reductase inhibitory actions; pharmacological properties in vivo
44. New nonsteroidal steroid 5 alpha-reductase inhibitors; syntheses and structure-activity studies on carboxamide phenylalkyl-substituted pyridones and piperidones
45. Gl-198745 Glaxo Wellcome
46. Kinetic analysis of LY320236; competitive inhibitor of type 1 and noncompetitive inhibitor of type 2 human steroid 5 alpha-reductase